PHYTONADIONE injection, emulsion

Phytonadione by

Drug Labeling and Warnings

Phytonadione by is a Prescription medication manufactured, distributed, or labeled by Cipla USA Inc., Cipla Limited, Immacule Lifesciences Private Limited. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • BOXED WARNING (What is this?)

    WARNING-HYPERSENSITIVITY REACTIONS WITH INTRAVENOUS AND INTRAMUSCULAR USE

    Fatal hypersensitivity reactions, including anaphylaxis, have occurred during and immediately after intravenous and intramuscular injection of phytonadione injectable emulsion. Reactions have occurred despite dilution to avoid rapid intravenous infusion and upon first dose. Avoid the intravenous and intramuscular routes of administration unless the subcutaneous route is not feasible and the serious risk is justified [see Warnings and Precautions (5.1)].

  • 1 INDICATIONS AND USAGE

    1.1 Treatment of Hypoprothrombinemia Due to Vitamin K Deficiency or Interference

    Phytonadione injectable emulsion is indicated for the treatment of the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity:

    • anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives;
    • hypoprothrombinemia due to antibacterial therapy;
    • hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis;
    • other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates.

    1.2 Prophylaxis and Treatment of Vitamin K-Deficiency Bleeding in Neonates

    Phytonadione injectable emulsion is indicated for prophylaxis and treatment of vitamin K-deficiency bleeding in neonates.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Dosing Considerations

    Whenever possible, administer phytonadione injectable emulsion by the subcutaneous route [see Boxed Warning]. When intravenous administration is unavoidable, inject the drug very slowly, not exceeding 1 mg per minute [see Warnings and Precautions (5.1)].

    Monitor international normalized ratio (INR) regularly and as clinical conditions indicate. Use the lowest effective dose of phytonadione injectable emulsion.

    The coagulant effects of phytonadione injectable emulsion are not immediate; improvement of INR may take 1-8 hours. Interim use of whole blood or component therapy may also be necessary if bleeding is severe.

    Whenever possible, administer benzyl alcohol-free formulations in pediatric patients [see Warnings and Precautions (5.2), Use in Specific Populations (8.4)].

    When phytonadione injectable emulsion is used to correct excessive anticoagulant-induced hypoprothrombinemia, anticoagulant therapy still being indicated, the patient is again faced with the clotting hazards existing prior to starting the anticoagulant therapy. Phytonadione is not a clotting agent, but overzealous therapy with phytonadione injectable emulsion may restore conditions which originally permitted thromboembolic phenomena. Dosage should be kept as low as possible, and INR should be checked regularly as clinical conditions indicate.

    2.2 Recommended Dosage for Coagulation Disorders from Vitamin K Deficiency or Interference

    The recommended dosage of phytonadione injectable emulsion is based on whether the hypoprothrombinemia is anticoagulant-induced (e.g., due to coumarin or indanedione derivatives) or non-anticoagulant-induced (e.g., due to antibiotics; salicylates or other drugs; factors limiting absorption or synthesis) as follows:

    • Anticoagulant-Induced Hypoprothrombinemia: Phytonadione injectable emulsion 2.5 mg to 10 mg or more subcutaneously, intramuscularly, or intravenously. Up to 25 mg to 50 mg may be administered as a single dose.

    Repeated large doses of phytonadione injectable emulsion are not warranted in liver disease if the initial response is unsatisfactory. Failure to respond to phytonadione injectable emulsion may indicate that the condition being treated is inherently unresponsive to phytonadione injectable emulsion.

    • Hypoprothrombinemia Due to Other Causes (Non-Anticoagulation-Induced Hypoprothrombinemia): Phytonadione injectable emulsion 2.5 mg to 25 mg or more intravenously, intramuscularly, or subcutaneously. Up to 50 mg may be administered as a single dose.

    Evaluate INR after 6-8 hours, and repeat dose if INR remains prolonged. Modify subsequent dosage (amount and frequency) based on the INR or clinical condition.

    2.3 Recommended Dosage for Prophylaxis and Treatment of Vitamin K Deficiency Bleeding in Neonates

    Prophylaxis of Vitamin K-Deficiency Bleeding in Neonates

    The recommended dosage of phytonadione injectable emulsion is 0.5 mg to 1 mg within one hour of birth for a single dose.

    Treatment of Vitamin K Deficiency Bleeding in Neonates

    The recommended dosage of phytonadione injectable emulsion is 1 mg given either subcutaneously or intramuscularly. Consider higher doses if the mother has been receiving oral anticoagulants.

    A failure to respond (shortening of the INR in 2 to 4 hours) may indicate another diagnosis or coagulation disorder.

    2.4 Directions for Dilution

    Dilute phytonadione injectable emulsion with 0.9% Sodium Chloride Injection, 5% Dextrose Injection, or 5% Dextrose and Sodium Chloride Injection. Avoid use of other diluents that may contain benzyl alcohol, which can cause serious toxicity in newborns or low birth weight infants [see Warnings and Precautions (5.2) and Use in Specific Populations (8.4)].

    When diluted, start administration of phytonadione injectable emulsion immediately after dilution.

    Discard unused portions of diluted solution as well as unused contents of the vial.

    Protect phytonadione injectable emulsion from light at all times.

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

  • 3 DOSAGE FORMS AND STRENGTHS

    Injection: 2 mg/mL and 10 mg/mL single-dose vials.

  • 4 CONTRAINDICATIONS

    Hypersensitivity to phytonadione or any other component of this medication [see Warnings and Precautions (5.1)].

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Hypersensitivity Reactions

    Fatal and severe hypersensitivity reactions, including anaphylaxis, have occurred with intravenous or intramuscular administration of phytonadione injectable emulsion. Reactions have occurred despite dilution to avoid rapid intravenous infusion and upon first dose. These reactions have included shock, cardiorespiratory arrest, flushing, diaphoresis, chest pain, tachycardia, cyanosis, weakness, and dyspnea. Administer phytonadione injectable emulsion subcutaneously whenever feasible. Avoid the intravenous and intramuscular routes of administration unless the subcutaneous route is not feasible and the serious risk is justified [see Dosage and Administration (2.1)].

    5.2 Risk of Serious Adverse Reaction in Infants due to Benzyl Alcohol Preservative

    Use benzyl alcohol-free formulations in neonates and infants, if available. Serious and fatal adverse reactions including "gasping syndrome" can occur in neonates and infants treated with benzyl alcohol-preserved drugs, including phytonadione injectable emulsion. The "gasping syndrome" is characterized by central nervous system depression, metabolic acidosis, and gasping respirations.

    When prescribing phytonadione injectable emulsion in infants, consider the combined daily metabolic load of benzyl alcohol from all sources including phytonadione injectable emulsion (contains 9 mg of benzyl alcohol per mL) and other drugs containing benzyl alcohol. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known [see Use in Specific Populations (8.1, 8.2 and 8.4)].

    5.3 Cutaneous Reactions

    Parenteral administration of vitamin K replacements (including phytonadione injectable emulsion) may cause cutaneous reactions. Reactions have included eczematous reactions, scleroderma-like patches, urticaria, and delayed-type hypersensitivity reactions. Time of onset ranged from 1 day to a year after parenteral administration. Discontinue phytonadione injectable emulsion for skin reactions and institute medical management.

  • 6 ADVERSE REACTIONS

    The following serious adverse reactions are described elsewhere in the labeling:

    • Hypersensitivity Reactions [see Warnings and Precautions (5.1)]
    • Cutaneous Reactions [see Warnings and Precautions (5.3)]

    6.1 Clinical Trials and Post-Marketing Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    The following adverse reactions have been identified during post-approval use of phytonadione injectable emulsion. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

    Cardiac Disorders: Tachycardia, hypotension.

    General disorders and administration site conditions: Generalized flushing; pain, swelling, and tenderness at injection site.

    Hepatobiliary Disorders: Hyperbilirubinemia

    Immune System Disorders: Fatal hypersensitivity reactions, anaphylactic reactions.

    Neurologic: Dysgeusia, dizziness.

    Pulmonary: Dyspnea.

    Skin and Subcutaneous Tissue Disorders: Erythema, pruritic plaques, scleroderma-like lesions, erythema perstans.

    Vascular: Cyanosis.

  • 7 DRUG INTERACTIONS

    Anticoagulants

    Phytonadione injectable emulsion may induce temporary resistance to prothrombin-depressing anticoagulants, especially when larger doses of phytonadione injectable emulsion are used. Should this occur, higher doses of anticoagulant therapy may be needed when resuming anticoagulant therapy, or a change in therapy to a different class of anticoagulant may be necessary (i.e., heparin sodium).

    Phytonadione injectable emulsion does not affect the anticoagulant action of heparin.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Phytonadione injectable emulsion contains benzyl alcohol, which has been associated with gasping syndrome in neonates. The preservative benzyl alcohol can cause serious adverse events and death when administered intravenously to neonates and infants. If phytonadione injectable emulsion is needed during pregnancy, consider using a benzyl alcohol-free formulation [see Warnings and Precautions (5.2), Use in Specific Populations (8.4)].

    Published studies with the use of phytonadione during pregnancy have not reported a clear association with phytonadione and adverse developmental outcomes [see Data]. There are maternal and fetal risks associated with vitamin K deficiency during pregnancy [see Clinical Considerations]. Animal reproduction studies have not been conducted with phytonadione.

    The estimated background risk for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

    Clinical Considerations

    Disease-associated maternal and/or embryo/fetal risk

    Pregnant women with vitamin K deficiency hypoprothrombinemia may be at an increased risk for bleeding diatheses during pregnancy and hemorrhagic events at delivery. Subclinical maternal vitamin K deficiency during pregnancy has been implicated in rare cases of fetal intracranial hemorrhage.

    Data

    Human Data

    Phytonadione has been measured in cord blood of infants whose mothers were treated with phytonadione during pregnancy in concentrations lower than seen in maternal plasma. Administration of vitamin K1 to pregnant women shortly before delivery increased both maternal and cord blood concentrations. Published data do not report a clear association with phytonadione and adverse maternal or fetal outcomes when used during pregnancy. However, these studies cannot definitively establish the absence of any risk because of methodologic limitations including small sample size and lack of blinding.

    Animal Data

    In pregnant rats receiving vitamin K1 orally, fetal plasma and liver concentrations increased following administration, supporting placental transfer.

    8.2 Lactation

    Risk Summary

    Phytonadione injectable emulsion contains benzyl alcohol. If available, preservative-free phytonadione injectable emulsion is recommended when phytonadione injectable emulsion is needed during lactation [see Warnings and Precautions (5.2), Use in Specific Populations (8.4)].

    Phytonadione is present in breastmilk. There are no data on the effects of phytonadione injectable emulsion on the breastfed child or on milk production. The developmental and health benefits of breastfeeding should be considered along with the clinical need for phytonadione injectable emulsion and any potential adverse effects on the breastfed child from phytonadione injectable emulsion or from the underlying maternal condition.

    8.4 Pediatric Use

    The safety and effectiveness of phytonadione injectable emulsion for prophylaxis and treatment of vitamin K deficiency have been established in neonates. Use of phytonadione injection for prophylaxis and treatment of vitamin K deficiency is based on published clinical studies.

    Serious adverse reactions including fatal reactions and the "gasping syndrome" occurred in premature neonates and infants in the intensive care unit who received drugs containing benzyl alcohol as a preservative. In these cases, benzyl alcohol dosages of 99 to 234 mg/kg/day produced high levels of benzyl alcohol and its metabolites in the blood and urine (blood levels of benzyl alcohol were 0.61 to 1.378 mmol/L). Additional adverse reactions included gradual neurological deterioration, seizures, intracranial hemorrhage, hematologic abnormalities, skin breakdown, hepatic and renal failure, hypotension, bradycardia, and cardiovascular collapse. Preterm, low-birth weight infants may be more likely to develop these reactions because they may be less able to metabolize benzyl alcohol.

    When prescribing phytonadione injectable emulsion in infants consider the combined daily metabolic load of benzyl alcohol from all sources including phytonadione injectable emulsion (phytonadione injectable emulsion contains 9 mg of benzyl alcohol per mL) and other drugs containing benzyl alcohol. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known [see Warnings and Precautions (5.2)].

    Whenever possible, use preservative-free phytonadione formulations in neonates. The preservative benzyl alcohol has been associated with serious adverse events and death in pediatric patients. Premature and low-birth weight infants may be more likely to develop toxicity.

  • 10 OVERDOSAGE

    Hemolysis, jaundice, and hyperbilirubinemia in newborns, particularly in premature infants, may result from phytonadione injectable emulsion overdose.

  • 11 DESCRIPTION

    Phytonadione is a vitamin K replacement, which is a clear, yellow to amber, viscous, odorless or nearly odorless liquid. It is insoluble in water, soluble in chloroform and slightly soluble in ethanol. It has a molecular weight of 450.70.

    Phytonadione is 2-methyl-3-phytyl-1, 4-naphthoquinone. Its empirical formula is C31H46O2 and its molecular structure is:

    structure

    Phytonadione injectable emulsion, USP is a clear yellow, sterile, aqueous colloidal solution of vitamin K1, with a pH of 4.5 to 7.0, available for injection by the intravenous, intramuscular, and subcutaneous routes. Phytonadione injectable emulsion, USP is available in 1 mg (2 mg/mL) and 10 mg (10 mg/mL) single-dose vials. Each milliliter of phytonadione injectable emulsion, USP contains the following inactive ingredients: 70 mg polyoxyl 35 castor oil, 37.5 mg dextrose monohydrate, 9 mg benzyl alcohol (preservative), and water for injection. Phytonadione injectable emulsion, USP contains glacial acetic acid for pH adjustment to 6.3 (4.5 – 7.0).

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Phytonadione injectable emulsion aqueous colloidal solution of vitamin K1 for parenteral injection, possesses the same type and degree of activity as does naturally-occurring vitamin K, which is necessary for the production via the liver of active prothrombin (factor II), proconvertin (factor VII), plasma thromboplastin component (factor IX), and Stuart factor (factor X). Vitamin K is an essential cofactor for a microsomal enzyme that catalyzes the post- translational carboxylation of multiple, specific, peptide-bound glutamic acid residues in inactive hepatic precursors of factors II, VII, IX, and X. The resulting gamma-carboxy-glutamic acid residues convert the precursors into active coagulation factors that are subsequently secreted by liver cells into the blood.

    In normal animals and humans, phytonadione is virtually devoid of activity. However, in animals and humans deficient in vitamin K, the pharmacological action of vitamin K is related to its normal physiological function, that is, to promote the hepatic biosynthesis of vitamin K dependent clotting factors.

    12.2 Pharmacodynamics

    The action of the aqueous dispersion, when administered intravenously, is generally detectable within an hour or two and hemorrhage is usually controlled within 3 to 6 hours. A normal INR may often be obtained in 12 to 14 hours.

    12.3 Pharmacokinetics

    Absorption:

    Phytonadione is readily absorbed following intramuscular administration.

    Distribution:

    After absorption, phytonadione is initially concentrated in the liver, but the concentration declines rapidly. Very little vitamin K accumulates in tissues.

    Elimination:

    Little is known about the metabolic fate of vitamin K. Almost no free unmetabolized vitamin K appears in bile or urine.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Studies of carcinogenicity, genotoxicity or impairment of fertility have not been conducted with phytonadione.

  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Phytonadione injectable emulsion, USP is a clear yellow, sterile, aqueous colloidal solution and is supplied in a package of 10 as follows:

    NDC No.
    		Container
    		Amount of Phytonadione injectable emulsion In Container
    		Volume
    		Concentration
    69097-709-96
    		 10 single-dose vials per carton
    		 1 mg
    		 0.5 mL
    		 2 mg/mL
    69097-708-96
    		 10 single-dose vials per carton
    		 10 mg
    		 1 mL
    		 10 mg/mL

    Store at 20° to 25°C (68° to 77°F); [see USP Controlled Room Temperature].

    Protect phytonadione injectable emulsion from light.  Store container in closed original carton until contents have been used.

  • 17 PATIENT COUNSELING INFORMATION

    Inform the patient of the following important risks of phytonadione injectable emulsion:

    Serious Hypersensitivity Reactions

    Advise the patient and caregivers to immediately report signs of hypersensitivity after receiving phytonadione injectable emulsion [see Warnings and Precautions (5.1)].

    Risk of Gasping Syndrome Due to Benzyl Alcohol

    Advise the patient and caregivers of the risk of gasping syndrome associated with the use of products that contain benzyl alcohol (including phytonadione injectable emulsion) in neonates, infants, and pregnant women [see Warnings and Precautions (5.2)].

    Cutaneous Reactions

    Advise the patient and caregivers to report the occurrence of new rashes after receiving phytonadione injectable emulsion. These reactions may be delayed for up to a year after treatment [see Warnings and Precautions (5.3)].

    Manufactured by: Cipla Ltd., India

    At M/s Immacule Lifesciences Pvt. Ltd. India

    Manufactured for:

    Cipla USA, Inc.

    10 Independence Boulevard, Suite 300,

    Warren, NJ 07059

    Revised: 3 /2022

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    NDC: 69097-709-30             RX Only

    Phytonadione

    Injectable Emulsion, USP

    1 mg/0.5 mL

    Neonatal Concentration

    0.5 mL Single-Dose Vial

    Contains no more

    than 500 mcg/L

    of aluminum.

    Protect from Light.

    Cipla

    containerlabel1mgper0pt5ml

    NDC: 69097-708-31           RX Only

    Phytonadione

    Injectable Emulsion, USP10 mg/ mL

    1 mL Single-Dose Vial

    Contains no more than

    500 mcg/L of aluminum.

    Protect from Light.

    Cipla

    contaner-label-10mg

    NDC: 69097-709-96            RX Only

    Phytonadione

    Injectable Emulsion, USP

    1 mg/0.5 mL

    Neonatal Concentration

    For INTRAMUSCULAR, SUBCUTANEOUS or

    INTRAVENOUS (with caution).

    Protect from light.

    Keep vials in carton until time of use.

    10 X 0.5 mL vials per carton

    Single-Dose Vials

    Cipla

    carton-label-1mg

    NDC: 69097-708-96            RX Only

    Phytonadione

    Injectable Emulsion, USP

    10 mg/ mL

    For INTRAMUSCULAR, SUBCUTANEOUS or

    INTRAVENOUS (with caution).

    Protect from light.

    Keep vials in carton until time of use.

    10 X 1 mL vials per carton

    Single-Dose Vials

    Cipla

    carton-labels-10mg
  • INGREDIENTS AND APPEARANCE
    PHYTONADIONE 
    phytonadione injection, emulsion
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 69097-709
    Route of AdministrationINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PHYTONADIONE (UNII: A034SE7857) (PHYTONADIONE - UNII:A034SE7857) PHYTONADIONE1 mg  in 0.5 mL
    Inactive Ingredients
    Ingredient NameStrength
    POLYOXYL 35 CASTOR OIL (UNII: 6D4M1DAL6O)  
    DEXTROSE MONOHYDRATE (UNII: LX22YL083G)  
    BENZYL ALCOHOL (UNII: LKG8494WBH)  
    WATER (UNII: 059QF0KO0R)  
    ACETIC ACID (UNII: Q40Q9N063P)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 69097-709-9610 in 1 CARTON04/27/2022
    10.5 mL in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21459604/27/2022
    PHYTONADIONE 
    phytonadione injection, emulsion
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 69097-708
    Route of AdministrationINTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    PHYTONADIONE (UNII: A034SE7857) (PHYTONADIONE - UNII:A034SE7857) PHYTONADIONE10 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    POLYOXYL 35 CASTOR OIL (UNII: 6D4M1DAL6O)  
    DEXTROSE MONOHYDRATE (UNII: LX22YL083G)  
    BENZYL ALCOHOL (UNII: LKG8494WBH)  
    WATER (UNII: 059QF0KO0R)  
    ACETIC ACID (UNII: Q40Q9N063P)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 69097-708-9610 in 1 CARTON04/27/2022
    11 mL in 1 VIAL; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21459604/27/2022
    Labeler - Cipla USA Inc. (078719707)
    Registrant - Cipla Limited (650138746)
    Establishment
    NameAddressID/FEIBusiness Operations
    Immacule Lifesciences Private Limited650694503manufacture(69097-708, 69097-709)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.